Biotech Values

[jq1234]

NVS initiate another pan-PI3K inhibitor BKM120 in combination with MEK162 in patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) which has progressed on EGFR inhibitors and triple negative breast cancer, as well as pancreatic cancer, colorectal cancer, malignant melanoma, NSCLC, and other advanced solid tumors with KRAS, NRAS, and/or BRAF mutations:

http://clinicaltrials.gov/ct2/show/NCT01363232?term=mek162&rank=2